• Essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level:
    • PO 1 tab OD

Tablet:

  • 5mg/1.25mg/5mg
  • 5mg/1.25mg/10mg
  • 10mg/2.5mg/10mg
  • To be taken in the morning before breakfast
  • Fixed dose combination is not suitable for initial therapy.

Perindopril: ACE Inhibitor.  It acts primarily on the suppression of the plasma renin-angiotensin aldosterone system thus decreasing plasma angiotensin II concentration, leading to decreased vasopressor activity and reduced aldosterone secretion.

Indapamide: Thiazide diuretic. It inhibits sodium reabsorption in distal renal tubules, resulting in increased excretion of water and of sodium, potassium and hydrogen ions.

Amlodipine: Dihydropyridine calcium channel blocker. It inhibits the influx of calcium ions into both vascular smooth muscle and cardiac muscle. The contraction of cardiac muscle and vascular smooth muscle are dependent on the movement of extracellular calcium ions into these cells by specific ion channels.

  • Headache
  • Dizziness
  • Vertigo
  • Sleepiness
  • Altered vision
  • Decreased blood pressure
  • Flushing
  • Breathlessness
  • Cough
  • Weight loss
  • Vomiting
  • Abdominal pain
  • Dryness in mouth
  • Indigestion
  • Hypersensitivity to the active substances, other sulfonamides, dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients
  • History of angioedema (Quincke’s edema) associated with previous ACE inhibitor therapy
  • Hereditary/idiopathic angioedema
  • Second and third trimesters of pregnancy
  • Hepatic encephalopathy
  • Severe hepatic impairment
  • Hypokalemia
  • Severe hypotension
  • Shock, including cardiogenic shock.
  • Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis).
  • Hemodynamically unstable heart failure after acute myocardial infarction.
  • Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60mL/min/1.73m2).
  • Extracorporeal treatments leading to contact of blood with negatively charged surfaces.
  • Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney.
  • Dialysis patients
  • Patients with untreated decompensated heart failure
  • Severe renal impairment (creatinine clearance below 30 mL/min)
  • Lithium
  • Aliskiren
  • Potassium-sparing drugs (e.g. triamterene, amiloride)
  • Heparin
  • Trimethoproim/sulfamethoxazole
  • Estramustine
  • Racecadotril
  • Sirolimus
  • Everolimus
  • Temsirolimus
  • Sacubitril/valsartan

                                   Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Triplixam 5mg/1.25mg/10mg Tablet 30’s Les Laboratoires Harley’s Ltd
Triplixam 10mg/2.5mg/10mg Tablet 30’s Les Laboratoires Harley’s Ltd
Triplixam 5mg/1.25mg/5mg Tablet 30’s Les Laboratoires Harley’s Ltd